Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2020

View Archived Issues

Circulating miR-638 and miR-521: potential screening biomarkers for cervical squamous cell carcinoma

Acid test for therapeutic peptides

Mersana begins phase I study of XMT-1592 in NSCLC and ovarian cancer

Interim phase I data presented for mRNA-1273 coronavirus vaccine

Cellect's ApoGraft to be studied for treatment of COVID-19-related pulmonary diseases

Namodenoson reduces liver fat and fibrosis in phase II NAFLD study

FDA clears IND application for phase II study of merimepodib in advanced COVID-19

LATS2 and KIBRA are prognostic markers in patients with ccRCC

Intermediary results presented for VLP COVID-19 vaccine in mice

Heron Therapeutics initiates phase Ib/II study of HTX-034 for postoperative pain

Human L-opsin gene therapy shows potential for treating blue cone monochromacy

Incyte presents novel PI3K-gamma inhibitors

Janssen discovers novel potent EP inhibitors

ELX-01 shows functional activity in a model of nonsense mutation-related IRD

Metacrine patents new AOC3 inhibitors

Arrien Pharmaceuticals synthesizes MELK and/or FLT3 inhibitors

Bristol-Myers Squibb presents new Toll-like receptor antagonists

New adjuvant reverses MDR in Gram-negatives

New ATR kinase inhibitors identified by Repare Therapeutics

Maxinovel Pharmaceuticals patents PD-1/PD-L1 interaction inhibitors

FDA approves Tecentriq for first-line metastatic NSCLC with high PD-L1 expression

Sorrento's STI-1499 demonstrates 100% inhibition of SARS-CoV-2 virus infection in vivo

European Commission grants conditional approval for Zolgensma for SMA

Phase IIb study of Liproca Depot in prostate cancer meets endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...